Inflection Biosciences

About:

Inflection Biosciences is a company that develops small-molecule therapeutics for the treatment of cancer.

Website: http://www.inflectionbio.com

Top Investors: Enterprise Ireland, EASME - EU Executive Agency for SMEs

Description:

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.

Total Funding Amount:

$738000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Blackrock, Dublin, Ireland

Founded Date:

2012-01-01

Contact Email:

info(AT)inflectionbio.com

Founders:

Darren Cunningham, Michael O’Neill

Number of Employees:

1-10

Last Funding Date:

2019-01-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai